haematology

News in brief: Liver failure fatality highlights risk of Hep B reactivation with rituximab; Potential paradigm shift in LBCL with CAR T-cell therapy; Lifelong anaemia risk after bariatric surgery

Liver failure fatality highlights risk of Hep B reactivation with rituximab The risk of hepatitis B reactivation must be considered in patients with haematological malignancy before prescribing B-cell-depleting therapies, according Australian clinicians who report a fatal case of liver failure in a patient treated with rituximab for B-cell lymphoma. Doctors at Austin Health said the ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic